TESARO, Inc. Form 8-K September 03, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 2, 2015

TESARO, Inc.

(Exact name of registrant as specified in its charter)


Delaware001-35587(state or other jurisdiction of incorporation)(Commission File Number)

27-2249687 (I.R.S. Employer Identification No.)

1000 Winter Street
Suite 3300
Waltham, Massachusetts
(Address of principal executive offices)

02451 (Zip Code)

(339) 970-0900 (Registrant s telephone number, including area code)



Item 7.01 Regulation FD Disclosure.

On September 2, 2015, TESARO, Inc. (the Company) issued a press release announcing the U.S. Food and Drug Administration $\,s\,$ (FDA) approval of VARUBI $\,$ (rolapitant). The press release announcing the approval is furnished as Exhibit 99.1 to this Form 8-K.

Item 8.01 Other Events.

On September 2, 2015, the Company announced that the FDA has approved VARUBI (rolapitant) in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1 Press Release of the Company dated September 2, 2015 announcing FDA approval of VARUBI .

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TESARO, Inc.

By: /s/ Joseph L. Farmer

Joseph L. Farmer

Senior Vice President, General Counsel and Secretary

Dated: September 3, 2015

3

EXHIBIT INDEX

Press Release of the Company dated September 2, 2015 announcing FDA approval of VARUBI .

4